Investor Presentaiton slide image

Investor Presentaiton

116 Investor presentation Full year 2022 EMEA at a glance EMEA Million 300 Diabetes trend Diabetes market by value and Novo Nordisk market share Novo Nordisk reported sales DKK billion 25% 120 Full year 2022 Sales (mDKK) Growth² 120% Total GLP-13 14,855 43% I 19% I I I 200 I Long-acting insulin4 7,157 4% GLP-1 90 90% Premix insulin5 2,622 -13% 35.22%¹ Fast-acting insulin 6,456 -2% I 100 60 260 195 158 60 3.14%1 Insulin 60% Human insulin 1,983 -10% Total insulin 18,218 -3% 30 30 OAD 30% Other Diabetes care? 717 -2% 12.45%¹ Diabetes care 33,790 13% 0 2021 0 0% Obesity care8 3,615 96% 2030 2045 Nov 2017 Nov 2022 Diabetes & Obesity 37,405 18% care Population with diabetes Diabetes growth rate GLP-1 MS -Insulin MS -OAD MS Rare disease⁹ 6,831 -1% Total 44,236 15% Diabetes trend estimates based on the following International Diabetes Foundation defined regions: Africa, Europe, Middle East and North Africa, South and Central America, South East Asia and Western Pacific Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021; EMEA: Europe, Middle East and Africa 1 CAGR calculated for 5-year period; Competitor insulin value market shares, as of Nov 2022: Novo Nordisk 48%, Sanofi 32% and Eli Lilly 16%; Competitor GLP-1 value market shares, as of Nov 2022: Novo Nordisk 61%, Eli Lilly 38% and AstraZeneca 2%; OAD: Oral anti-diabetic; MS: Market share; Source: IQVIA MAT, Nov 2022 value figures 2 At Constant exchange rates; 3 Comprises Victoza®, OzempicⓇ, and RybelsusⓇ; 4 Comprises Tresiba®, XultophyⓇ and Levemir®; 5 Comprises RyzodegⓇ and NovoMixⓇ: 6 Comprises FiaspⓇ and NovoRapidⓇ; 7 Comprises Novo NormⓇ and needles; 8 Obesity care comprises SaxendaⓇ and Wegovy®; 9 Comprises primarily NovoSeven®, Novo Eight® NovoThirteen®, Esperoct®, RefixiaⓇ, Norditropin, Vagifem® and Activelle®
View entire presentation